Search and filter

The All Wales Medicines Strategy Group conducts health technology assessments to evaluate new and existing medicines for use in NHS Wales. The main aim of this process is to ensure that patients in Wales have timely access to safe, effective, and cost-efficient medicines. This briefing describes the AWMSG appraisal process, which typically follows a structured procedure that involves submission, evaluation, and final recommendations.

The Beneluxa Initiative on Pharmaceutical Policy is a multi-country horizon scanning, HTA and pricing and reimbursement collaboration between Belgium, the Netherlands, Luxembourg, Austria and Ireland.

Cost-utility models sit at the centre of economic evidence development for access, providing a structured way to compare the additional costs and health benefits of new interventions with those of established alternatives.

Digital and modular value platforms are a distinct category of value communication tools that sit alongside global value dossiers, payer submissions and interactive payer tools. They provide a controlled environment in which evidence, narratives and tools are organised, updated and deployed to support access teams globally and locally.

The HAS’s structured approach to economic evaluation follows a robust process to ensure transparency, efficiency, and equity in healthcare decision-making. By integrating rigorous analyses with stakeholder engagement, the process balances cost-effectiveness with patient access to innovative treatments. This comprehensive methodology supports the long-term sustainability of the healthcare system while maintaining its commitment to high-quality patient care.

The Joint Scientific Consultation framework is a core component of European Union Regulation (EU) 2021/2282 on health technology assessment, through which health technology developers can discuss planned evidence generation with a subgroup of the Member State Coordination Group on Health Technology Assessment and receive non-binding scientific recommendations intended to inform a later Joint Clinical Assessment.

FINOSE started in 2018 as a Nordic collaboration to conduct joint health technology assessments (HTAs) of medicines and was relaunched as the Joint Nordic HTA Bodies (JNHB) in June 2024.

Global value dossiers and their local adaptations are central instruments for organising and communicating the value proposition of new medicines to payers, acting as internal reference documents that consolidate clinical, economic and contextual evidence, while also providing the structure from which country- or region-specific submissions are derived.

The French National Authority for Health (Haute Autorité de Santé, HAS) has in place a structured action plan issued in 2020 to adopt evaluation processes for innovative medicines. The plan focuses on three core initiatives: issuing conditional opinions for early access, implementing real-world monitoring to confirm efficacy and safety, and streamlining assessments for high-value medicines.

The Haute Autorité de Santé (HAS, National Authority for Health) offers an Early Dialogue scientific advice service to guide pharmaceutical companies in designing pivotal clinical trials for innovative medicinal products. This voluntary and confidential service provides non-binding recommendations to optimise evidence generation for Health Technology Assessments, focusing on unmet medical needs and aligning with national requirements.

The Health Economics Methods Advisory (HEMA) is a collaborative initiative established to enhance the evaluation methods used in health technology assessments (HTAs). It brings together experts three health technology assessment agencies to critically assess and refine health economic methodologies.

The French Health Technology Assessment (HTA) process, overseen by the French National Authority for Health (Haute Autorité de Santé, HAS), is a comprehensive evaluation system designed to assess the medical, economic, and public health value of pharmaceuticals. This process informs decisions regarding the reimbursement and pricing of medications within the French healthcare system.

HTA and reimbursement intelligence platforms aggregate health technology assessment outcomes, reimbursement decisions, pricing, regulatory and clinical data across multiple jurisdictions. Their primary function is to give a structured view of how payers have assessed similar products, what evidence has been required, and how coverage and prices have evolved over time.

An international collaboration of health technology assessment (HTA) bodies from UK, Australia and Canada was established in 2021 and expanded when Québec’s National Institute of Excellence in Health and Social Services (Institut national d’excellence en santé et en services sociaux, INESSS) and New Zealand’s Pharmac joined in 2023.

Health technology assessment bodies in the United Kingdom, Canada, Australia and New Zealand have formalised a collaboration to address common evidence and methods challenges. The International Health Technology Assessment Collaboration brings together national and sub-national agencies with a focus on work sharing, horizon scanning and methods development, including new approaches to joint scientific advice.